Document:

Amendment to 

GenVec, Inc. 2011 Omnibus Incentive Plan

 

 

The GenVec, Inc. 2011 Omnibus Incentive
Plan (the “Plan”) is hereby amended as follows:

 

		1.	Section 4.1 of the Plan is hereby amended in its entirety to read as follows:

 

Subject
to adjustment as provided under the Plan, the total number of shares of Stock that are available for Awards under the Plan shall
be equal to the sum of (i) nine hundred forty thousand (940,000) shares of Stock, (ii) the number of shares of Stock available
for awards under the Prior Plan as of the Effective Date and (iii) the number of shares of Stock subject to awards outstanding
under the Prior Plan as of the Effective Date which thereafter (a) terminate by expiration, forfeiture, cancellation, or otherwise
without the issuance of such shares of Stock, (b) are settled in cash in lieu of such shares of Stock or (c) are exchanged for
the Committee’s permission, before the issuance of such shares of Stock, for compensatory awards not involving shares of
Stock. Such shares of Stock may be authorized and unissued shares or treasury shares or any combination of the foregoing, as may
be determined from time to time by the Board or by the Committee. Any of the authorized shares of Stock may be used for any type
of Award under the Plan, and any or all of the shares of Stock may be allocated to Incentive Stock Options.

 

		2.	Except as amended above, the Plan shall remain in full force and
effect.

 

IN WITNESS WHEREOF,
GenVec, Inc. has executed this amendment to the Plan, as of this 11th day of July, 2012.

 

 

GENVEC, INC.

 

 

	 	 	 	 	 
		 	By:	/s/ Douglas J. Swirsky	 
		 	Name:	Douglas J. Swirsky 	 
		 	Title:	Chief Financial OfficerLICENSE AGREEMENT 

 

 

This
License Agreement (the "Agreement"), which shall be effective as of July 13, 2012, is by and between Global Cancer Diagnostics
Inc., an Arizona corporation ("GCDx") and Radient Pharmaceuticals Corporation, a Delaware corporation ("RXPC");
and. 

 

Whereas,
the GCDx wishes to hold an exclusive global license to a blood test for lung cancer (the “LC Test”), procedures, analyses,
data, manufacturing processes, components, trademarks and intellectual property identified in Exhibit A (the "Intellectual
Property"); 

 

Whereas, RXPC desires
to grant a license to GCDx to commercialize a Lung Cancer Test (the “LC Test”) into the global market;

 

Whereas, GCDx will
not make, use of or sell any other RXPC test using the DR-70 reagents and will be the only company offering a test specific to
lung cancer,

 

In
consideration of the recitals, mutual
promises, covenants, representations, warranties, and
agreements contained herein, and intending to be legally bound,
the Parties agree as follows: 

 

		1.	Definitions 

 

		1.1	"Confidential Information"
means any confidential or proprietary information including non-public technical designs, specifications,
drawings, dimensions, processes, practices, communications,
manufacturing, economic,
financial, sales,
marketing, management, quality control
and other proprietary data, materials, know-how, or information related to the Licensed Products
or Intellectual Property as contained in presentations,
e-mails, letters, memos, discussions, notes, analyses, documents,
practices, studies,
reports, budgets, forecasts,
and other media of disclosure, which may have been disclosed by either Party to the other
Party in verbal, written, graphic, computer or machine recognizable, and/or tangible form, and which is clearly designated, labeled
or marked as confidential, e.g. "CONFIDENTIAL",
"PROPRIETARY," or its equivalent.

 

		1.2	"FDA"
means the U.S. Food and Drug Administration.

 

		1.3	"Intellectual Property
Rights" means any patents in any country, trade names,
trademarks, trade secrets, copyright, copyrightable expression or work, and any other intellectual
property rights that exist or may exist in or are related to the Licensed Know-how or the Tests.

 

		1.4	"Licensed Know-how" means laboratory
journals, series, measurement reports, test reference
values, technical designs, ornamental designs, specifications,
formulas, drawings,
dimensions, tests, reports, analyses,
processes, practices, communications, compositions
and sources of all reagents, buffers, supplies and materials relative to quality control of
the Tests described in Exhibit A, referred to in this document as the LC Test. 

 

		1.5	"Licensed Patents and Pending Patents" means the patents
listed in Exhibit A and any (i) continuation, divisional,
continuation-in-part, reissue, extension, renewal, re-examination,
and substitute thereof; (ii) foreign patent or patent application,
including any foreign patent or patent application claiming priority to or otherwise constituting a counterpart of the patents
listed in Schedule 1;
and (iii) patent issuing
from such applications in any country. 

 

    	 

    	 	

    
 

		1.6	"Licensed Products" means the LC Tests listed in Exhibit
A, which may be updated from time to time upon the mutual written consent of the Parties. 

 

		1.7	"Licenses" means
the rights and licenses granted by RXPC to GCDx under this agreement. 

 

		1.8	"New Products" means any technologies or diagnostics related
to the Licensed Patents or Licensed Know-how. 

 

		1.9	"Party(ies)" means GCDx, RXPC or both, as the case may be.

 

		1.10	“Royalty(ies”) means the royalty payments
due in accordance with Exhibit B.

 

		1.11	"Royalty Period"
means each calendar quarter during the term of this Agreement.

 

		1.11	"Subsidiary(ies)" means any corporation, GCDx, affiliate, or other entity, whose outstanding
shares or securities representing the right to vote for the election of directors or other managing authority are, now or hereafter,
owned or controlled, directly or indirectly by a Party, but such corporation, company, affiliate, or other entity shall be deemed
to be a Subsidiary only so long as such ownership or control exists.

 

		1.13	"Territory" means any and all countries in the world.

 

		1.14	"Tests"
means the tests, procedures, analyses, data, manufacturing
processes, components, and intellectual property related to the tests described in Exhibit
A as of the date of this Agreement.

 

		1.15	“ Net Sales” means the gross amount received by GCDx for sales of any product or service to Third Parties, less
the following deductions or allowances, but only to the extent consistent with Generally Accepted Accounting Principles.

 

		a.	Trade, quantity, or cash discounts or rebates, chargebacks, commissions, Medicaid/Medicare rebates, and allowances.

 

		b.	Sales, use, value added, inventory and excise taxes, import and customs duties, tariffs and any other similar taxes, duties
tariffs or other governmental charges (but excluding income taxes) that effectively reduce net selling price; and

 

		c.	Amounts repaid or credits taken by reason of rejections, outdating defects, or returns or because of retroactive price reductions
or due to recalls or government laws or regulations requiring rebates.

 

		d.	Minus amounts expended relating to special equipment acquired in the performance of the work (i.e. the additional cost to cover
the acquisition of specialized equipment whether or not itemized for the Third Party).

  

		1.15	"Valid
                                                                                                Claim" means a claim of any
                                                                                                granted Licensed Patent that has
                                                                                                not been withdrawn, cancelled
                                                                                                or disclaimed, nor held invalid
                                                                                                or unenforceable by a court of
                                                                                                competent jurisdiction. 

 

    	 

    	 	

    
 

		1.15	“Health Canada” means the Medical Devices Bureau of the Health Protection Branch of the Canadian government.

 

		2.	License Grant 

 

		2.1	RXPC hereby grants to GCDx, and
GCDx accepts, a right and license under the Licensed
Know-how within the Territory to: 

 

(a) use, make, have made,
modify, import, export, distribute, market, advertise,
offer for sale, sell
and otherwise dispose of the Licensed Products; 

 

(b) practice any process and method
or use any apparatus in the manufacture of Licensed Products by or on behalf of GCDx; and

 

		2.3	The Licenses are transferable
only upon written approval
by RXPC, although able to be sublicensed by
GCDx, subject to the terms of this Agreement. RXPC will consider requests
for transferability and
will not unreasonably withhold approval of transfer provided
such a transfer would not adversely affect the rights
and obligations of RXPC. 

 

		2.4	The Licenses granted herein shall be limited to the Licensed Products,
as set forth on Exhibit A. RXPC shall have the right to grant additional licenses utilizing
the Licensed Patents or Licensed Patents, Licensed Know-How and/or Pending Patents, provided that such additional licenses do not
directly compete with the Licensed Products.

 

		3.	License Fee

 

		3.1	The License Fee for the Licensed Products includes the following:

 

		3.1.1	GCDx will pay an up-front license fee of two hundred thousand dollars ($200,000) (the “Up-Front
License Fee) to RXPC within thirty (30) days of the signing of this license agreement.

 

		3.1.2	GCDx will pay all costs related to the prosecution of all U.S. Patents directly related to the
LC Test using the Licensed Products.

 

		3.1.3	GCDx will pay all costs related to the filing of any PCT application at the appropriate time as
reasonably determined by GCDx directly related to the LC Test using the Licensed Products but within one year of filing of any
U.S. patent.

 

		3.1.4	RXPC is free to file and prosecute foreign patents in countries around the world that are not related
to the manufacture or sale of the reagents and the Lung Cancer Test.

 

		3.1.5	GCDx will pay all costs related to developing the Licensed Products for commercial applications,
including process development costs, clinical study costs and costs related to the FDA filing and approval process.

 

		3.1.6	GCDx and RXPC agree that continued development, improvement, validation, refinement and/or enhancement
of the Test for commercialization purposes including Clinical Studies or trials and protocol improvements will be necessary for
the U.S. FDA approval of the LC Test as a screening test for lung cancer. GCDx and RXPC will meet quarterly to discuss the Intellectual
Property and mutually determine what Intellectual Property-related actions should be taken to protect the Intellectual Property
for global commercialization purposes, maintenance of the Intellectual Property rights and protection of the exclusive license
of the Licensed Products and Intellectual Property. Such mutually agreed upon actions, shall be managed and administered by GCDx
for the benefit of RXPC.

 

    	 

    	 	

    
 

		4.	Royalty Payments, Transfer Fees,
Reporting and Auditing 

 

		4.1	During the term of this Agreement,
from and after the commercial introduction of a Licensed Product, GCDx
agrees to pay to the RXPC a royalty as specified in
Exhibit A. The GCDx
royalties shall be earned only upon actual receipt of payment
of revenue or sublicense license fees and sublicense royalty fees by
GCDx, as adjusted for the value
of any returns, allowances,
discounts, freight, transportation, insurance, and sales taxes or other similar taxes included in such gross revenue or fees. 

 

		4.2	After the commencement of royalty payments to RXPC by GCDx, GCDx
will provide to RXPC within the 35
days following the last day of each Royalty
Period (each calendar quarter) a report showing the royalties
due in accordance with Exhibit B for the Royalty Period, and
will submit therewith any royalty payment due for such
Royalty Period. All payments to GCDx shall be payable in
US Dollars. RXPC shall
bear all sales or use taxes arising from royalty payments
made to RXPC by GCDx under this Agreement, and RXPC shall be responsible for reporting and
paying all taxes based on income to RXPC. If
required by state or
local law, GCDx shall
withhold the amount of taxes levied by state or local governments
on payments made by GCDx pursuant to this Agreement and
shall make payments of the
withheld amount to the local tax
authorities and shall
provide to RXPC official tax receipts to enable RXPC to support a claim for tax credit with
respect to such withheld taxes so paid by RXPC.

 

		4.3	GCDx shall maintain complete and accurate records
of the sale of Licensed Products and
for royalties received from sub-licensees on the sale of Licensed Products in
accordance with generally accepted accounting principles. GCDx shall retain records for at least three years after the close of
any Royalty Period. RXPC may, at any time during the three-year
period following its receipt of a report specified in Section
4.2, initiate an independent audit of the records
of GCDx relating to the Royalty Period covered
by such report, upon 10 prior business days written notice
to GCDx, in order to confirm the accuracy of the GCDx records
and conformance with the terms and conditions of this Agreement;
provided, that no more than one such audit is conducted for any 12 month period. The selection
of an independent auditor shall be mutually
agreeable to both Parties.
The independent auditor must execute a written confidentiality agreement with GCDx
before entering GCDx premises
or gaining access to any Confidential Information of GCDx.

 

		4.4	Other than that necessary to conduct the audit. The independent auditor
shall report to RXPC only the fact of compliance or the specific discrepancies of non-compliance with respect to the royalty obligations
under this Agreement. Any such audit requested by RXPC shall be performed at RXPC’s expense
during GCDx normal business hours.
If an audit reveals that GCDx has underpaid payments due to RXPC by more than 5% for a Royalty
Period, and such disparity is not the result of timing differences which have resulted in the royalty payments being reported on
any previous report or to be included on a subsequent report under the GCDx method
of recognizing revenue, then GCDx will reimburse the reasonable
costs of RXPC in conducting the audit, in addition to any underpaid amounts. 

 

		5.	Licensed Product Introduction 

 

		5.1	GCDx and the RXPC
agree that it is the intent of the Parties to commercialize the LC Test as quickly as possible.

 

    	 

    	 	

    
 

		5.2	GCDx and RXPC
agree that continued development, improvement, validation,
refinement and/or enhancement of the Test for commercialization
purposes, including clinical studies and protocol improvements, are necessary. Additionally, both parties recognize that further
advancements, improvements and additions to the Intellectual
Property may be necessary. GCDx and the RXPC will meet
quarterly to discuss the Intellectual Property and determine
what Intellectual Property-related actions are required to ensure adequate product protection for global commercialization
purposes, maintenance of the RXPC Intellectual Property
Rights and protection of the GCDx exclusive
license of the Intellectual Property Rights. Each party will pay the amounts required for
such activities.

 

		5.3	If GCDx
requests additional assistance from RXPC over and above the plan(s)
described in Section 3.1.5 in order to advance the commercialization of a Licensed Product,
RXPC agrees to make its scientific staff available for consultation, general assistance,
testimonials, support
and providing other technical information to GCDx
pertaining to such
Licensed Product. Upon written agreement as to the time and expenses
required for such support, GCDx agrees to pay RXPC or
its designee, at the rate of $150 per hour for approved and agreed upon services, plus any pre-approved
out-of-pocket expenses, including travel expenses
if the services are performed outside of the Phoenix Metropolitan Area.
At the end of any monthly period in which services are provided or expenses
are incurred, RXPC will provide to GCDx a detailed written invoice of the services
provided, the fees,
and the expenses incurred,
with applicable receipts attached. GCDx
will pay RXPC within 30 days after receipt of invoices
in proper form.

 

		5.4	All discoveries, improvements, and inventions which are
directly related to the Licensed Products or Licensed Know-how and which are made, created, developed, written, conceived or reduced
to practice in the performance of this Agreement shall be the sole and exclusive property of the RXPC.

 

		5.5	Except as otherwise expressly
provided in this Agreement, neither Party grants,
nor agrees to grant, a license to any other intellectual property right held by that Party
to the other Party, whether by implication, estoppel, or otherwise.

 

		6.	Registration of Product 

 

		6.1	GCDx will be responsible for registering
the Licensed Product(s) as may be required by the various countries in which a Licensed Product may be sold. This registration
process, including FDA approval(s) and approvals by Health Canada, with all accompanying expenses, including additional clinical
tests and data as may be required, will be paid solely by GCDx.

 

		6.2	RXPC hereby gives GCDx
all necessary rights to all available clinical and development studies relating to the Licensed Products that were prepared by
or are owned by RXPC or to which RXPC has rights, for use in filing any and all product registrations,
as may be required or appropriate. RXPC will also assist GCDx, as requested and without additional
cost, in seeking rights to other related data and tests. 

 

		6.3	GCDx will prepare or cause to
be prepared and submitted an application for registration or exemption to the United States Food and Drug Administration for the
Licensed Products promptly from the date of the successful completion of an FDA clinical study. This registration and all other
required registrations throughout the territory will be solely at the expense of GCDx.
Notice of any registration filings and receipt of any registrations will be provided to RXPC within
10 days of filing of said registration or receipt of notice of registration by GCDx.

 

    	 

    	 	

    
 

		6.4	GCDx will file additional product
registration applications as it deems necessary to enter relevant markets. 

 

		6.5	GCDx will regularly inform RXPC
of the status of the activities with regard to the registration and the granting of the registrations. 

 

		7.	Non-Compete 

 

		7.1	RXPC agrees that RXPC will not grant to any entity the right to sell the Licensed Products for
any purpose that would directly compete with the Licensed Products during the term of the Agreement. This also includes the sale
of a Licensed Product in a re-packed form or a resale. Notwithstanding the foregoing, RXPC shall have the right to license the
Licensed Know-How, Licensed Patents and Pending Patents to other parties as long as such additional licenses do not directly compete
with the Licensed Products.

 

		8.	Confidential Information 

 

		8.1	The Parties acknowledge that Confidential Information
may be disclosed by RXPC to GCDx and/or disclosed by GCDx to RXPC and both parties may be
"Discloser" and "Recipient" in this Section as is appropriate under the circumstances. Confidential Information
which is disclosed verbally must be identified by Discloser to Recipient as confidential at the time of disclosure or must be
confirmed in writing by the Discloser within 30 days after such disclosure to be classified as Confidential Information.

 

		8.2	The Parties hereby agree that Recipient shall (i) not
disclose, publish, distribute, transfer, loan, provide, or otherwise make available the Confidential Information to any third
party without written consent of Discloser, (ii) restrict dissemination of Confidential Information to only those directors, officers,
employees, representatives, advisors, contractors, consultants, or agents who must be directly involved with Confidential Information
and who are bound by a duty of confidentiality applicable to the Confidential Information, (iii) use the same degree of care as
for its own information of like importance, but at least use reasonable care, in safeguarding against disclosure of Confidential
Information of the other Party, and (iv) use the Confidential Information solely for exercising its rights or performing its obligations
under this Agreement.

 

		8.3	Recipient's obligations regarding Confidential Information received under this Agreement expire
five years from the date of termination of this Agreement.

 

		8.4	This Agreement imposes no obligation upon Recipient with respect to Confidential Information disclosed
under this Agreement which (i) is now available or becomes available to the public without breach of this Agreement, (ii) is explicitly
approved for release by written authorization of Discloser, (iii) is lawfully obtained from a third party without a duty of confidentiality,
(iv) is disclosed to a third party by Discloser without a duty of confidentiality, (v) is known to Recipient prior to such disclosure,
or (vi) is at any time developed by Recipient independently of any such disclosure(s) from Discloser.

 

		8.5	RXPC’s rights to publish will not be unduly or unreasonably limited by GCDx provided that
any such intended publication(s) will not hinder or jeopardize potential future patent filing(s) and/or confidential disclosures
made. The rights of GCDx to publish will not be unduly or unreasonably limited by RXPC provided that any such intended publication(s)
will not hinder or jeopardize potential future patent filing(s) and/or confidential disclosures made.

 

    	 

    	 	

    
 

		8.6	Disclosure of Confidential Information shall not be precluded if such disclosure is (i) in response
to a valid order of a court of competent jurisdiction, or (ii) otherwise required by law through no act of the Recipient, provided,
however, that in the event of a court order, the Recipient shall first notify the Discloser of such court order in a timely manner
to allow the Discloser time to obtain a protective order requiring that the information and/or documents so disclosed be used only
for the purpose for which the order was issued.

 

		8.7	Recipient agrees that all Confidential Information received is and will remain the property of
Discloser and that such shall not be copied or reproduced without the express permission of the Discloser, except for such copies
as may be absolutely necessary in order to perform tasks pursuant to this Agreement. Upon written request, Recipient will either
return all the Confidential Information to Discloser along with all copies and/or derivatives made, including that on computer
databases and copies of portions of the Confidential Information, or destroy all Confidential Information and certify by written
memorandum that all such Confidential Information has been destroyed, except that Recipient may retain archival copies of the Confidential
Information, which are to be used only in case of a dispute concerning this Agreement.

 

		9.	Warranties, Indemnification, and Disclaimer 

 

		9.1	RXPC warrants that it will use its best efforts to achieve
the best possible result with the care common in the field of work and under consideration of the state of the art known to it.
The warranty of RXPC only extends to the documentation to be delivered as well as to the agreed consultation services. Possible
defects will only be corrected by way of re-working. Unless otherwise negotiated and agreed to by both parties, the term for the
correction of defects is six weeks after delivery of the documentation or provision of the service.

 

		9.2	Both Parties represent and warrant that each has all necessary right and authority to enter into
this Agreement and agree to the terms and conditions of this Agreement without violating its articles of organization or operating
agreement or any agreements with third parties.

 

		9.3	RXPC represents and warrants that it has good and marketable title to the Licensed Know-how, Licensed
Patents and Tests and the sole right to grant exclusive licenses to the Licensed Know-how, Licensed Patents and Tests, free and
clear of all security interests, liens, encumbrances, mortgages, assignments, claims, licenses, and charges of any kind or nature.
RXPC further represents and warrants that, to the best of its knowledge, no other entity has a claim of ownership or interest in
the Licensed Know-how, Licensed Patents and Tests that would conflict with or interfere with the GCDx exercise of, or quiet enjoyment
of, the rights and licenses granted in this Agreement. RXPC agrees, upon request, to provide to GCDx
evidence or other proof it may have or may reasonably obtain as to its sole right, title, and interest in and to the Licensed Know-how,
Licensed Know-how, Licensed Patents and Tests.

 

		9.4	RXPC hereby grants to GCDx without additional consideration,
a license under the terms of this Agreement to any and all future Intellectual Property Rights which are owned , developed, discovered,
invented, created, improved upon, conceived, or authored by RXPC or employees, agents, or contractors thereof, and which are necessary
or convenient for RXPC to manufacture and sell the Licensed Product in the Territory. RXPC
represents and warrants that it shall maintain ownership of any and all such Intellectual Property Rights during the term of this
Agreement.

 

    	 

    	 	

    
 

		9.5	RXPC declares at the date of signing of the Agreement
there are no pending or threatened infringement actions against any Licensed Products, and further, to the best of its knowledge,
that the Licensed Products do not infringe on any third party intellectual property rights.

 

		9.6	RXPC declares at the date of signing of the Agreement,
that no third party is infringing any right under the Intellectual Property Rights and further, to the best of its knowledge,
that the Intellectual Property does not infringe on any third party intellectual property rights.

 

		9.7	Each Party to this Agreement agrees to indemnify the
other Party, and hold the other Party harmless, from and against all claims, damages, costs and expenses (including attorney's
fees) attributable, directly or indirectly, to the breach by the indemnifying party of any obligation hereunder or the inaccuracy
of any representation or warranty made by the indemnifying party herein and in any instrument delivered pursuant hereto or in
connection with the transactions contemplated hereby. The Parties agree that the total liability of either Party shall not exceed
the amount paid to RXPC in the form of the license fees and royalties.

 

		9.8	Each Party agrees to notify the other Party in writing
if it becomes aware of any infringement with respect to the Intellectual Property. Upon becoming aware of a third party which
is manufacturing or selling products or conducting other activities that infringe upon any of the rights granted to GCDx
under this Agreement with respect to the Intellectual Property, GCDx at its sole election
and sole cost and benefit may pursue litigation or other action against any third party that GCDx
reasonably believes is manufacturing or selling products or conducting other activities that infringe upon any of the rights
granted to GCDx under this Agreement with respect to the Intellectual Property. GCDx
shall retain control over the action, responsibility for all costs and expenses, and sole authority to settle any action
that it initiates. RXPC agrees to cooperate fully with GCDx in the pending action or litigation,
but will not be required to join as a party thereto.

 

		9.9	RXPC agrees to defend, indemnify, and hold GCDx
harmless based upon a claim that the Licensed Product as furnished to GCDx hereunder
by RXPC directly infringes any patent, copyright, trade secrets, or other intellectual property rights of others and to pay the
total costs and damages finally awarded in any such suit, provided that RXPC notifies GCDx promptly
in writing of the suit. RXPC's obligation to pay costs
and damages under this Section
shall not exceed the amount
paid by GCDx in the form
of License Fees and
Royalties and shall be
in the form of a reduction
in the future royalties due from GCDx
under Section 3, and its sub-licensee(s) up
to a maximum of 50% of royalties
due for the applicable Royalty Period until such
damages and costs are paid in full.

 

		9.10	IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL,
OR CONSEQUENTIAL DAMAGES ARISING UNDER THIS AGREEMENT REGARDLESS OF WHETHER OR NOT EITHER PARTY WAS ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES. 

 

		10.	Term and Termination 

 

    	 

    	 	

    
 

		10.1	This Agreement
shall become effective upon the date of signing by both Parties and
continue in effect until the earlier to occur of: (i)
expiration of the last patent issued
to RXPC for the Licensed Products, (ii) when GCDx
terminates this Agreement by discontinuing the offering of
the Licensed Products or the
sublicense to do the same.
GCDx shall be deemed to have discontinued the offering
of the Licensed Products
when GCDx no longer offers,
or has reasonable offers
for, any of the Licensed Products
and no longer receives
revenue from any unaffiliated
third party, other than GCDx,
from sales of any of the Licensed Products
during any full calendar year. At such date the license
rights will by default
return to RXPC, or (iii) by RXPC in the event that GCDx does not achieve sales necessary
to meet the Minimum Royalty Payments, as set forth in Exhibit B, for any two consecutive fiscal quarters.

 

		10.2	Either Party shall
have the right to terminate this Agreement or seek remedies
under Section 11 for any material breach under this Agreement,
including a failure of the other Party
to perform pursuant to the terms and conditions of this Agreement, 30
days after the Party sends written notice thereof to the other Party, unless the other Party cures the failure
before the end of the 30-day notice period or by a later date if
mutually agreed in writing
by both Parties.

 

		10.3	Within 10 days of any government imposed order, injunction,
or prohibition against sales of the Licensed
Product (a "Government
Order"), either Party may elect, with notice in writing to the other Party,
to impose a 360-day cure period to attempt
to remove or negate the Government
Order. RXPC may terminate this Agreement immediately
if GCDx fails to elect
the 360-day cure period within the 10-day election period. RXPC releases GCDx
from its obligation to pay any royalties under Section 3 during the term of the Government
Order only for the Territory within
the realm and jurisdiction of the government that imposed
the order. The Parties agree
to work together and mutually seek and implement a remedy or
cure to the Government Order that is within the reasonable control and resources of
the Parties and does not cause unreasonable burden or hardship.
If the Government Order is removed
and GCDx begins again to manufacture and sell Licensed Products, the royalty
payments under Section 3 shall resume. 

 

		10.4	This Agreement and any rights or licenses granted herein are personal
to each Party and shall be binding upon and inure to the
benefit of the Parties hereto
and their respective successors and assigns. GCDx
shall ensure that any acquiring party or assignee shall assume at least the
rights and obligations so assigned and transferred.

 

		10.5	If either
party terminates the Agreement or the Agreement expires
due to nonpayment or otherwise, any and all license rights
will revert to RXPC. Three months after the
date of reversion, RXPC
will be entitled to enter new contractual agreements with third parties with regard
to such rights.

 

		11.	Alternate Dispute Resolution

 

		11.1	Each Party waives, to the fullest
extent permitted by applicable law, any
right it may have to
a trial by a court of competent jurisdiction, including a
trial by jury, with respect
to any dispute (as defined in Section 10.2).

 

		11.2	With regard to any dispute arising under this agreement ("Disputes"), the Parties agree
to discuss the possibility of binding mediation, and if the Parties fail to agree to binding mediation or if non-binding mediation
fails to resolve the dispute within 30 days, the Parties agree to submit disputes for binding arbitration. It is expressly intended
by the Parties that disputes shall be submitted to arbitration and not to litigation.

 

    	 

    	 	

    
 

		11.3	The arbitration shall be commenced by written demand
for arbitration to the other Party with a copy to the American Arbitration Association ("AAA") in Phoenix, Arizona.
The arbitration shall be administered by the AAA in accordance with the Federal Arbitration Act, 9 U.S.C. (1995) ("FAA")
and pursuant to the AAA's rules for arbitration, provided that such rules do not conflict with the FAA or the express intentions
of the Parties in this Agreement. In the case of any such conflict, the FAA and/or the express intentions of the parties shall
prevail over the AAA's rules.

 

		11.4	There shall be one arbitrator. If the Parties cannot agree on the selection of an arbitrator, the
arbitrator shall be selected by the AAA.

 

		11.5	The prevailing party in the arbitration shall be entitled
to recover damages and costs, including the arbitrators' fees and reasonable attorneys' fees, to be fixed by the arbitrator in
such proceeding. The Parties, however, agree that the amount of the damages and the costs shall not exceed the total amount paid
to RXPC by GCDx.

 

		11.6	The arbitrator shall issue a written statement as to his/her decision. In no circumstances shall
the arbitrator have the power or authority to award equitable, provisional or injunctive relief. The Parties agree that the decision
of the arbitrator will be final and binding and that no appeal can be taken to any forum or jurisdiction.

 

		12.	Miscellaneous Provisions

 

		12.1	Nothing herein shall be construed as forming a partnership
or joint venture between the Parties. Neither Party shall represent or commit the other in any way. Neither Party's employees
shall be considered employees or contractors of the other.

 

		12.2	Any notice, request, demand, payment or other communication required or permitted hereunder shall
be in writing and shall be deemed to have been given if delivered in person, upon receipt, or if sent by professional overnight
courier such as Fed Ex, DHL or UPS, upon the date on which delivery is made. All notices to a Party will be sent to the address
set forth below or to such other address or person as such Party may designate by notice to the other party hereunder:

 

To GCDx:

 

Global Cancer Diagnostics Inc..

10645 North Tatum Blvd., Suite 200-551

Phoenix, Arizona 85028

Attention: President

 

 

			To RXPC:

 

Radient Pharmaceuticals Corporation 

2492 Walnut Avenue, Suite 100 

Tustin, California 92780 

Attention: President

 

		12.3	This Agreement is complete and embodies the entire agreement
of the Parties with respect to its subject matter, and supersedes and merges all prior discussions between them, and neither of
the Parties shall be bound by any conditions, definitions, warranties, understandings, or representations with respect to such
subject matter other than as expressly provided herein. This Agreement made can be modified only in a writing signed by a proper
and duly authorized officer or representative of the Party to be bound thereby.

 

    	 

    	 	

    
 

		12.4	This agreement shall be interpreted and construed according to the laws of the State of Arizona,
USA, without regard to laws or principles relating to conflicts of laws.

 

		12.5	If for any reason a court of competent jurisdiction finds
any provision of this Agreement, or a portion thereof, to be unenforceable, that provision of the Agreement shall be enforced
to the maximum extent permissible so as to affect the intent of the Parties, and the remainder of this Agreement shall continue
in full force and effect. Failure by either Party to enforce any provision of this Agreement shall not be deemed a waiver of future
enforcement of that or any other provision.

 

		12.6	Anything contained in this Agreement to the contrary notwithstanding, the obligations of the Parties
hereto shall be subject to all laws, both present and future, of any government having jurisdiction over either Party hereto, and
to orders or regulations of any such government, or any department, agency, or court thereof. The Parties hereto shall be excused
from any failure to perform any obligation hereunder to the extent such failure is caused by any court injunction, law, order,
regulation, or contingency but only so long as the injunction, law, order, regulation or contingency continues.

 

		12.7	Any delay or failure of either Party to perform its obligations
hereunder shall be excused to the extent that it is caused by any other event or occurrence beyond its reasonable control such
as, by way of example and not by way of limitation, acts of God, actions by any governmental authority (whether valid or invalid),
fires, floods, windstorms, explosions, riots, natural disasters, acts of war or sabotage.

 

		12.8	Each Party agrees that it will not in any form export,
re-export, resell, ship or divert or cause to be exported, re-exported, resold, shipped or diverted, directly or indirectly, any
product or technical data or documentation furnished hereunder to any country for which the United States Government or any agency
thereof at the time of export or re-export requires an export license or other governmental approval without first obtaining such
license or approval.

 

		12.9	All references herein to the masculine, neuter or singular
shall be construed to include the masculine, feminine, neuter or plural, where applicable. Whenever the words "include",
"includes" or "including" are used in this Agreement, they shall be deemed to be followed by the words "without
limitation." Except as has been expressly provided to the contrary herein, nothing in this Agreement is intended, nor shall
be deemed, to confer upon any person or legal entity other than RXPC and GCDx, any rights or remedies under or by reason of this
Agreement.

 

		12.10	The Section headings contained in the Agreement are for
reference purposes only and will not affect the meaning or interpretation of this Agreement in any way. A reference to
a numbered Section in this Agreement refers to a Section in this Agreement. All Appendices to this Agreement shall be attached
hereto and are incorporated herein by this reference as though fully set forth herein. Any reference to an "Appendix"
shall mean an Appendix to this Agreement.

 

		12.11	The Parties are each knowledgeable and cognizant. The
language in all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly
for or against either party. This Agreement has been negotiated in good faith with contributions from both Parties and as such
shall not be construed against either Party by nature of their contributions.

 

    	 

    	 	

    
 

		12.12	This Agreement may be signed in separate counterparts, which taken together shall constitute one document. Signatures hereunder
may be provided by facsimile or electronic pdf version and shall have the same force and effect as originals.

 

IN WITNESS WHEREOF, the Parties
hereto have executed this Agreement as of the date set forth above.

 

	 	Global Cancer Diagnostics Inc., an Arizona Corp.
	 	 
	 	 
	 	 
	 	Name:	William Gartner
	 	 	CEO

 

RADIENT PHARMACEUTICALS CORP., A Delaware Corporation 

	
	 	 	 
	 
	Name:	 	Douglas C. MacLellan
	 	 	CEO

   

    	 

    	 	

    
 

Exhibit A

 

		A.	Technology Licensed.

 

			All Intellectual Property and Know-how related to a blood test for Lung Cancer, as listed in Patent and Trademark Tables below.

 

 

 

    	 

    	 	

    
 

EXHIBIT
B

 

Royalty
Payments.

 

		1.1	Royalty Rate. GCDx will pay a royalty equal to $400 per DR-70 kit made, used or sold by
GCDx in the Territory.

 

		1.2	Minimum Royalties. GCDx shall pay RCPC an annual minimum royalty according to the following
schedule:

 

	Calendar Year 2013	 	$	100,000	 
	 	 	 	 	 
	Calendar Year 2014	 	$	300,000	 
	 	 	 	 	 
	Each Calendar Year thereafter	 	$	400,000	 

 

		1.3	Minimum royalties for each Calendar Year will be paid on a quarterly basis beginning in Calendar
Year 2014, and become due 35 days after the last day of each Calendar Quarter for that year. GCDx has the right to continue to
pay the minimum royalties specified in this Section 1.2 in order to keep the Licenses in good standing.

 

		1.4.	All royalties paid pursuant to Section 1.1 shall be cumulative for purposes of determining if any
minimum royalty payment is due under Section 1.2. Accordingly, for any given Royalty Period, and taking into account the total
sum of royalties paid to RXPC to date in such calendar year, GCDx shall make the minimum royalty payment, or portion thereof, under
Section 1.2 if and only to the extent necessary to make up any shortage in the cumulative minimum royalty payment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]